Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

July 2, 2010

Primary Completion Date

February 11, 2014

Study Completion Date

December 19, 2016

Conditions
Melanoma
Interventions
BIOLOGICAL

Immunotherapeutic GSK2302025A, different formulations

Intramuscular administration

Trial Locations (37)

13385

GSK Investigational Site, Marseille

13585

GSK Investigational Site, Berlin

16132

GSK Investigational Site, Genoa

20089

GSK Investigational Site, Rozzano (MI)

20133

GSK Investigational Site, Milan

20141

GSK Investigational Site, Milan

23538

GSK Investigational Site, Lübeck

24105

GSK Investigational Site, Kiel

30625

GSK Investigational Site, Hanover

33075

GSK Investigational Site, Bordeaux

35042

GSK Investigational Site, Rennes

44093

GSK Investigational Site, Nantes

45122

GSK Investigational Site, Essen

47014

GSK Investigational Site, Meldola (FC)

47900

GSK Investigational Site, Rimini

48100

GSK Investigational Site, Ravenna

51092

GSK Investigational Site, Reims

54511

GSK Investigational Site, Vandœuvre-lès-Nancy

55131

GSK Investigational Site, Mainz

59037

GSK Investigational Site, Lille

66421

GSK Investigational Site, Homburg

68167

GSK Investigational Site, Mannheim

72076

GSK Investigational Site, Tübingen

80131

GSK Investigational Site, Napoli

90419

GSK Investigational Site, Nuremberg

115478

GSK Investigational Site, Moscow

197758

GSK Investigational Site, Saint Petersburg

357502

GSK Investigational Site, Pyatigorsk

454087

GSK Investigational Site, Chelyabinsk

656 53

GSK Investigational Site, Brno

500 05

GSK Investigational Site, Hradec Králové

128 08

GSK Investigational Site, Prague

07740

GSK Investigational Site, Jena

80-215

GSK Investigational Site, Gdansk

60-693

GSK Investigational Site, Poznan

76-200

GSK Investigational Site, Słupsk

Unknown

GSK Investigational Site, Saint Petersburg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01149343 - Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer | Biotech Hunter | Biotech Hunter